Results 71 to 80 of about 14,439 (224)

Implementation and use of risk minimization control tools in the EU: A multistakeholder survey

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink   +21 more
wiley   +1 more source

The biosimilars journey: current status and ongoing challenges

open access: yes, 2018
Biosimilar products are already approved and marketed in several countries. The Food and Drug Administration has approved ten different biosimilars, and the European Medicines Agency has approved 40.
Daniel Egg Neto   +3 more
core   +1 more source

Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access

open access: yesComparative Economic Research, 2020
The EU approved the first biosimilar drug in 2006. By 2017, the EU had authorized the highest number of biosimilars worldwide, acquiring considerable experience in their use and safety.
Olga Barszczewska   +2 more
doaj   +1 more source

Analysis of regulatory review models and approval timelines across selected African medicines regulatory authorities using the OpERA framework (2020–2024)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background The World Health Organization (WHO) developed the Global Benchmarking Tool (GBT) to assess national regulatory systems and support regulatory‐system strengthening across regulatory functions. Several African National Medicines Regulatory Authorities (NMRAs) have achieved Maturity Level 3 (ML3).
Constance Sakala Chisha   +10 more
wiley   +1 more source

Biosimilars in dermatology

open access: yesAdvances in Dermatology and Allergology, 2015
Over the last decade the availability of biological drugs for the treatment of psoriasis vulgaris, psoriatic arthritis and many other inflammatory diseases has revolutionized the treatment of these diseases around the world. Due to the high cost of therapy, the search has started for biosimilars.
Mazur, Małgorzata   +4 more
openaire   +2 more sources

Adapting the WHO Global Competency Framework for Regulators of Medicines: Implementation lessons from the South African Health Products Regulatory Authority

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Medicines regulatory authorities require skilled staff to ensure timely, consistent and high‐quality regulatory decision making. The World Health Organization Global Competency Framework (WHO‐GCF) for Regulators of Medicines provides a common reference for defining regulatory workforce competencies while allowing adaptation to local needs.
Goonaseelan Pillai   +9 more
wiley   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

open access: yesBiotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga   +2 more
wiley   +1 more source

Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies

open access: yesDrug Metabolism and Pharmacokinetics, 2019
The concept of biosimilar was established in the early 2000s in EU. Currently, the regulatory framework for biosimilar has also been established in the US, Japan, and other countries. As of 2018, biosimilars for infliximab, adalimumab, rituximab, trastuzumab, and bevacizumab have been approved.
Akiko, Ishii-Watabe, Takashi, Kuwabara
openaire   +2 more sources

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease. [PDF]

open access: yesJPGN Rep
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Himelstein D   +5 more
europepmc   +2 more sources

Measuring the Outcomes of International Oncology Regulatory Collaboration in Canada from 2019 to 2025: Project Orbis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Project Orbis, launched by the US FDA in 2019, enables collaboration among international regulatory agencies on cancer drug reviews. We assessed the regulatory impact of Project Orbis in Canada by analyzing publicly available data on marketing authorization applications (MAAs).
Jonathan Zaslavsky, David C. Sealey
wiley   +1 more source

Home - About - Disclaimer - Privacy